SERBIA PROCURES NEW MEDICINE AGAINST COVID-19: Reduces mortality by about 50 percent, has shown exceptional results in clinical trials!

Foto: Tanjug

Molnupiravir should be used as oral antiviral therapy to treat mild to moderate COVID-19 infection in adults.

MSD Director for Serbia, Bosnia and Herzegovina, Albania and Montenegro Nebojša Škuljec says that by helping patients treat the early stages of the disease, the course of the pandemic can be reversed.

MSD announced that it started the production of the drug at its own risk, i.e. without previous regulatory approvals, but that it also expects to produce 10 million therapeutic protocols by the end of the year, as well as an increase in production during 2022.

According to Skuljec, that company has a long tradition in researching infectious diseases and is dedicated to finding a quick response for the COVID-19 pandemic.

In addition to the development of Molnupiravir, MSD is said to be contributing to the pandemic response through collaboration with Johnson & Johnson in support of their vaccine production and supply.

President Aleksandar Vučić said on Friday that Serbia, along with America, will be the first to have MSD drugs.

Foto: ST/Privatna arhiva

The director of the Republic Health Insurance Fund (RFZO), Sanja Radojević Škodrić, told Tanjug that the drug showed exceptional results in clinical studies.

She added that it should be registered with the American Food and Drug Administration (FDA) by the end of the year and then with the European Medicines Agency (EMA).

- Immediately after registration, the countries that signed the agreement will receive this medicine. The countries that signed the agreements secured not only the right to be the first ones to receive the medicine, but also to receive the quantities needed for their citizens - said Radojević Škodrić.